Advertisement
Advertisement
PRME
Prime Medicine, Inc. Common Stock
3.58
USDSponsored
+0.33
+10.34%
Feb 06, 15:59 UTC -5
Closed
After-Market
3.54
-0.03
-0.95%
PRME Earnings Reports
Positive Surprise Ratio
PRME beat 3 of 12 last estimates.
25%
Next Report
Date of Next Report
Feb 27, 2026
Estimate for Q4 25 (Revenue/ EPS)
$2.39M
/-$0.25
Implied change from Q3 25 (Revenue/ EPS)
+94.89%
/-21.88%
Implied change from Q4 24 (Revenue/ EPS)
+9.36%
/-19.35%
Prime Medicine, Inc. Common Stock earnings per share and revenue
On Nov 07, 2025, PRME reported earnings of -0.32 USD per share (EPS) for Q3 25, missing the estimate of -0.25 USD, resulting in a -23.98% surprise. Revenue reached 1.23 million, compared to an expected 1.05 million, with a 17.04% difference. The market reacted with a -8.85% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 14 analysts forecast an EPS of -0.25 USD, with revenue projected to reach 2.39 million USD, implying an decrease of -21.88% EPS, and increase of 94.89% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were Prime Medicine, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Prime Medicine, Inc. Common Stock reported EPS of -$0.32, missing estimates by -23.98%, and revenue of $1.23M, 17.04% above expectations.
How did the market react to Prime Medicine, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -8.85%, changed from $4.18 before the earnings release to $3.81 the day after.
When is Prime Medicine, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 27, 2026.
What are the forecasts for Prime Medicine, Inc. Common Stock's next earnings report?
Based on 14
analysts, Prime Medicine, Inc. Common Stock is expected to report EPS of -$0.25 and revenue of $2.39M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement